updat model incorpor aet invest thesi tie deal
despit rel conserv assumpt lack revenue synergi dcf analysi
yield pt upsid think compel particularli
see limit downsid current level
model incorpor contribut aet transact
updat model incorpor contribut aet transact start
estimate aet contribut op profit includ synergi
includ increment synergi lead adj ep
second year follow complet transact despit
rel conserv assumpt across busi segment lack revenue
synergi deploy increment cash flow benefit tax reform toward
debt paydown assum debt paydown
result adj leverag ratio management expect
resum share repurchas achiev management target adj leverag ratio
low see opportun upsid est revenue synergi cash
estimate pbm net revenue growth toward mid-point guidanc
retail/ltc net revenue growth in-lin guidanc total net revenue
growth toward high-end guidanc estim
pbm total adj claim toward mid-point guidanc estimate
retail/ltc compstore growth in-lin guidanc same-stor adj
script toward mid-point guidanc estimate pbm op profit
growth consist guidanc low- mid-singl digit retail/ltc op
profit growth consist guidanc low-singl digit total adj op profit
growth compar guidanc
share reflect attract risk/reward see limit downsid aet deal isnt
recogn uncertainti whether deal approv regul
put updat estim risk howev deal doesnt go dont see
lot downsid think share would like fall worst current
current year estim compar previou stand-alon ep
would suggest downsid
updat estim price target
lower adj ep estimate rais adj ep estimate
rais pt base revis dcf analysi
impli share trade adj ep estimate current
multipl
pleas see page report import disclosur
posit near term strong pbm busi well long
term posit health reform integr pbm/ retail busi model
believ manag steer compani right direct number
long-term growth driver cah/cv sourc jv grow clinic busi
pharmaci advisor coram still see favor risk/reward think
core hold healthcar investor
 clarifi aet
 top-lin growth retail/ltc
revenu pbm revenu
 gross margin consider
y/i due growth pbm segment
contract retail/ltc segment
 share count share
 strong retail comp better macro
environ coupl better pbm
 stronger gener lower
 share repo
 struggl retail/ltc
 weaker expect gener
greater expect reimburs
 lower share repo anticip
one largest drug retail chain compani larg oper
two main busi segment pharmaci servic retail pharmaci
retail pharmaci segment compani oper drugstor on-line retail
pharmaci websit well health clinic store sell prescript drug
wide array gener merchandis refer front end product
compani also provid full rang pbm servic client mainli includ
organ sponsor health benefit plan servic includ formulari
servic diseas manag program pharmacogenom servic
million except per-shar data
cowen compani
model assumptionstermin growth tax depreci chang net work termin valuefre free futur excess number per year end decemb cowen
million except per-shar data
compani report cowen compani
interseg good interseg cost good gener amort ex-deal oper expens tax provis tax incom continu incom intang earli extinguish discontinu loss non-controlling financ wtd averag ep cont chang year end decemb cowen
million except per-shar data
compani report cowen compani
interseg good interseg cost good gener amort ex-deal oper expens tax provis tax incom continu incom alloc particip intang earli extinguish discontinu loss non-controlling financ wtd averag ep cont chang cowen
million
compani report cowen compani
asset cash receiv incom current equip asset liabil account discount portion long-term current incom non-curr non-controlling equiti common held comprehens sharehold sharehold liabil stockhold liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti year end decemb cowen
million
compani report cowen compani
income/ loss flow oper activ depreci earli extinguish sale incom tax non-cash oper asset liabil account receiv current long-term net cash oper acquisit common treasuri dividend secur debt net increase/ decreas cash equival begin cash equival end summari oper exclud non-recur itemsfor year end decemb cowen
million
compani report cowen compani
flow oper activ net reconcil net earn net cash depreci earli extinguish sale incom tax non-cash oper asset liabil account receiv current long-term cash provid oper flow invest activitiespurchas properti sale-lease-back sale properti net cash acquir available-for-sal short-term matur available-for-sal sale sale dispos cash use invest flow financ activitiesincreas decreas short-term debt assum issuanc long-term long-term non-controlling interest exercis stock tax benefit stock-bas common cash provid use financ exchang rate decreas cash cash cash equival begin cash equival end year end decemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
see number risk associ drug retail space industri highli
competit retail drugstor chain independ pharmaci mail-ord provid
well retail includ groceri store mass merchant warehous club on-line
store compet space could pressur front-end sale margin
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind part believ
could concern around sustain high growth area
believ impact ppaca expect increas volum could subdu
depend implement execut
regulatori approv acquisit aet lower expect
guidanc later expect roll-on contract
